

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in this application:

**Listing of Claims:**

Claim 1. (Currently amended) A propellant free pharmaceutical composition, comprising:

- (a) a tiotropium salt (1); and
- (b) a salmeterol salt (2) selected from a chloride, bromide, sulfate, phosphate or methane sulfonate salt,

optionally in the form of the enantiomers, mixtures of enantiomers, or in the form of the racemates thereof, optionally in the form of the solvates or hydrates and optionally together with a pharmaceutically acceptable excipient.

Claim 2. (Original) The pharmaceutical composition according to claim 1, wherein the tiotropium salt (1) and the salmeterol salt (2) are contained in a single preparation.

Claim 3. (Original) The pharmaceutical composition according to claim 1, wherein the tiotropium salt (1) and the salmeterol salt (2) are contained in two separate preparations.

Claim 4. (Original) The pharmaceutical composition according to claim 1, wherein the tiotropium salt (1) is a chloride, bromide, iodide, methanesulfonate, *para*-toluenesulfonate, or methylsulfate salt.

Claim 5. (Cancelled)

Claim 6. (Cancelled)

Claim 7. (Original) The pharmaceutical composition according to claim 1, wherein the relative amount of the tiotropium salt (1) to the salmeterol salt (2) are in a range from 1:300 to 30:1 based upon the ratios by weight of tiotropium (1') to salmeterol (2').

RESPONSE TO OFFICE ACTION 12/24/2004  
U.S. Appln. No. 10/054,567

Claim 8. (Original) The pharmaceutical composition according to claim 1, wherein the relative amount of the tiotropium salt (1) to the salmeterol salt (2) are in a range from 1:230 to 20:1 based upon the ratios by weight of tiotropium (1') to salmeterol (2').

Claim 9. (Original) The pharmaceutical composition according to claim 1, wherein a single administration corresponds to a dosage of the active substance combination 1' and 2' of from 0.01 µg to 1000 µg.

Claim 10. (Original) The pharmaceutical composition according to claim 1, wherein a single administration corresponds to a dosage of the active substance combination 1' and 2' of from 0.01 µg to 200 µg.

Claim 11. (Original) The pharmaceutical composition according to one of claims 1-~~to 10 -4~~  
and 7-10, wherein the pharmaceutical composition is in a form suitable for inhalation administration.

Claim 12. (Original) The pharmaceutical composition according to claim 11, wherein the pharmaceutical composition is an inhalable powder.

Claim 13. (Cancelled)

Claim 14. (Cancelled)

Claim 15. (Original) The pharmaceutical composition according to claim 11, wherein the pharmaceutical composition is an inhalable powder, further comprising a suitable physiologically harmless adjuvant selected from monosaccharides, disaccharides, oligo- and polysaccharides, polyalcohols, salts, or mixtures thereof.

Claim 16. (Original) The inhalable powder according to claim 15, wherein the adjuvant has a maximum mean particle size of up to 250 µm.

Claim 17. (Original) The inhalable powder according to claim 16, wherein the adjuvant has a maximum mean particle size of between 10 µm and 150 µm.

RESPONSE TO OFFICE ACTION 12/24/2004  
U.S. Appln. No. 10/054,567

Claim 18. (Original) A capsule containing the inhalable powder according to claim 15.

Claim 19. (Original) A capsule containing the inhalable powder according to claim 16.

Claim 20. (Original) A capsule containing the inhalable powder according to claim 17.

Claim 21. (Original) The inhalable powder according to claim 12, consisting essentially of the tiotropium salt (1) and the salmeterol salt (2).

Claim 22. (Cancelled)

Claim 23. (Cancelled)

Claim 24. (Cancelled)

Claim 25. (Cancelled)

Claim 26. (Cancelled)

Claim 27. (Cancelled)

Claim 28. (Original) The inhalable propellant-free solution according to claim 41, further comprising a solvent selected from water, ethanol, or a mixture of water and ethanol.

Claim 29. (Original) The inhalable propellant-free solution according to claim 28, wherein the pH of the solution is in the range of 2 to 7.

Claim 30. (Original) The inhalable propellant-free solution according to claim 29, wherein the pH of the solution is in the range of 2 to 5.

Claim 31. (Original) The inhalable propellant-free solution according to claim 29, wherein the pH is adjusted using an acid selected from hydrochloric acid, hydrobromic acid, nitric

RESPONSE TO OFFICE ACTION 12/24/2004  
U.S. Appln. No. 10/054,567

acid, sulfuric acid, ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid, and propionic acid, or mixtures thereof.

Claim 32. (Original) The inhalable propellant-free solution according to claim 28, further comprising an additional cosolvent or adjuvant.

Claim 33. (Original) The inhalable propellant-free solution according to claim 32, wherein the additional cosolvent has one or more hydroxyl or other polar groups.

Claim 34. (Original) The inhalable propellant-free solution according to claim 33, wherein the additional cosolvent is an alcohol, glycol, glycerol, polyoxyethylene alcohol, or polyoxyethylene fatty acid ester.

Claim 35. (Original) The inhalable propellant-free solution according to claim 33, wherein the additional cosolvent is isopropyl alcohol, propylene glycol, polyethylene glycol, polypropylene glycol, glycol ether, glycerol, polyoxyethylene alcohol, or a polyoxyethylene fatty acid ester.

Claim 36. (Original) The inhalable propellant-free solution according to claim 32, wherein the adjuvant is selected from a surfactant, stabilizer, complexing agent, antioxidant, preservative, flavoring, pharmacologically harmless salt, or vitamin.

Claim 37. (Original) The inhalable propellant-free solution according to claim 32, wherein the adjuvant is edetic acid or a salt of edetic acid.

Claim 38. (Original) The inhalable propellant-free solution according to claim 32, wherein the adjuvant is ascorbic acid, vitamin A, vitamin E, or a tocopherols.

Claim 39. (Original) The inhalable propellant-free solution according to claim 32, wherein the adjuvant is cetylpyridinium chloride, benzalkonium chloride, benzoic acid, or a benzoate.

RESPONSE TO OFFICE ACTION 12/24/2004  
U.S. Appln. No. 10/054,567

Claim 40. (Original) The inhalable propellant-free solution according to claim 141, consisting essentially of: the tiotropium salt (1), the salmeterol salt (2), benzalkonium chloride, sodium edetate, and the solvent.

Claim 41. (Original) The inhalable propellant-free solution according to claim 141, consisting essentially of: the tiotropium salt (1), the salmeterol salt (2), benzalkonium chloride, and the solvent.

Claim 42. (Original) The inhalable propellant-free solution according to claim 141, wherein the inhalable propellant-free solution is a concentrate or sterile ready-to-use solution for inhalation.

Claim 43. (Currently amended) A method of administering the inhalable propellant-free solution according to claim 14 to a patient, comprising nebulizing the inhalable propellant-free solution in an inhaler according to Figures Ia or Ib WO 91/14468 or an inhaler as described in Figures 6a and 6b of WO 97/12687.

Claim 44. (Original) A method of administering the inhalable propellant-free solution according to claim 14 to a patient, comprising nebulizing the inhalable propellant-free solution in an energy-operated free-standing or portable nebulizer which produces inhalable aerosols by means of ultrasound or compressed air according to the Venturi principle or other principles.

Claim 45. (Currently amended) A method of treating a respiratory disease, the method comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to one of claims 1, 4, ~~5, 6,~~ 7, 8, 9, or 10.

Claim 46. (Original) The method according to claim 45, wherein the respiratory disease is asthma or COPD.